

Published Articles - Methods

Measuring preferences for living in U.S. states: a comparison of the rating scale, time trade-off, and standard gamble, Ackerman SJ;Beusterien KM;Mafilios MS;Wood MR;, 1998, Acad Radiol, 5 Suppl 2

Evidence synthesis, parameter correlation and probabilistic sensitivity analysis, Ades AE;Claxton K;Sculpher M;, 2006, Health Econ, 15

Bayesian methods for evidence synthesis in cost-effectiveness analysis, Ades AE;Sculpher M;Sutton A;Abrams K;Cooper N;Welton N;Lu G;, 2006, Pharmacoeconomics, 24

Is health-related quality of life a sustainable outcome measure for evaluating health promotion programmes, Ashley A;Lloyd AJ;Lamb S;Bartlett H;, 2001, NT Research, 6

Characterizing Structural Uncertainty in Decision Analytic Models: A Review and Application of Methods, Bojke L;Claxton K;Sculpher M;Palmer S;, 2009, Value Health,

A systematic and critical review of the process of translation and adaptation of generic health-related quality of life measures in Africa, Asia, Eastern Europe, the Middle East, South America, Bowden A;Fox-Rushby JA;, 2003, Soc Sci Med, 57

Methods for pre-testing and piloting survey questions: illustrations from the KENQOL survey of health-related quality of life, Bowden A;Fox-Rushby JA;Nyandieka L;Wanjau J;, 2002, Health Policy Plan, 17

Making decisions under uncertainty--the role of probabilistic decision modelling, Bravo VY;Sculpher M;, 2006, Fam Pract, 23

Quality-adjusted life years, Bravo VY;Sculpher M;, 2008, Pract Neurol, 8

Missing... presumed at random: cost-analysis of incomplete data, Briggs A;Clark T;Wolstenholme J;Clarke P;, 2003, Health Econ, 12

Parametric modelling of cost data: some simulation evidence., Briggs A;Nixon R;Dixon S;Thompson S;, 2005, Health Econ, 14

Sensitivity analysis in economic evaluation: a review of published studies., Briggs A;Sculpher MJ;, 1995, Health Econ, 4

Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis, Briggs A;Sculpher MJ;, 1994, Health Econ, 3

The design and analysis of stochastic cost-effectiveness studies for the evaluation of health care interventions., Briggs A;Tambour M;, 2001, Drug Information Journal, 35

A Bayesian approach to stochastic cost-effectiveness analysis, Briggs AH;, 1999, Health Econ, 8

A Bayesian approach to stochastic cost-effectiveness analysis. An illustration and application to blood pressure control in type 2 diabetes, Briggs AH;, 2001, Int J Technol Assess Health Care, 17

New methods of analysing cost effectiveness, Briggs AH;, 2007, British Medical Journal, 335

Statistical approaches to handling uncertainty in health economic evaluation, Briggs AH;, 2004, Eur J Gastroenterol Hepatol, 16

Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework, Briggs AH;Ades AE;Price MJ;, 2003, Med Decis Making, 23

Power and sample size calculations for stochastic cost-effectiveness analysis, Briggs AH;Gray AM;, 1998, Med Decis Making, 18

The death of cost-minimization analysis?, Briggs AH;O'Brien BJ;, 2001, Health Econ, 10

An introduction to Markov modelling for economic evaluation., Briggs AH;Sculpher MJ;, 1998, Pharmacoeconomics, 13

Markov models of medical prognosis., Briggs AH;Sculpher MJ;, 1997, British Medical Journal, 314

Stopping of clinical trials, Buxton M;Sculpher M;, 1994, Lancet, 343

Do Patient charge increases reduce the use of prescription medicines?, Buxton MJ;Sculpher MJ;, 1991, Public Money and Management, 11

Decision making heuristics and the elicitation of preferences: being fast and frugal about the future, Cairns J;van der PM;Lloyd A;, 2002, Health Econ, 11

A glossary of economic terms, Chiba N;Gralnek IM;Moayyedi P;Provenzale D;Inadomi JM;Willan AR;Briggs AH;Kim WR;, 2004, Eur J Gastroenterol Hepatol, 16

Value based pricing for NHS drugs: an opportunity not to be missed?, Claxton K;Briggs A;Buxton MJ;Culyer AJ;McCabe C;Walker S;Sculpher MJ;, 2008, British Medical Journal, 336

Discounting and cost-effectiveness in N, Claxton K;Sculpher M;Culyer A;McCabe C;Briggs A;Akehurst R;Buxton M;Brazier J;, 2006, Health Econ, 15

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra, Claxton K;Sculpher M;McCabe C;Briggs A;Akehurst R;Buxton M;Brazier J;O'Hagan T;, 2005, Health Econ, 14

Using value of information analysis to prioritise health research: some lessons from recent UK experience, Claxton KP;Sculpher MJ;, 2006, Pharmacoeconomics, 24

Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence, Culyer A;McCabe C;Briggs A;Claxton K;Buxton M;Akehurst R;Sculpher M;Brazier J;, 2007, J Health Serv Res Policy, 12

Transferability of economics evaluations across jurisdictions: ISPOR Good Practices Task Force Report, Drummond M;Barbieri M;Cook J;Glick H;Lis J;Malik F;Reed SD;Rutten F;Sculpher M;Severens J;, , Value Health, 12

Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies, Drummond M;Manca A;Sculpher M;, 2005, Int J Technol Assess Health Care, 21

Common methodological flaws in economic evaluations, Drummond M;Sculpher M;, 2005, Med Care, 43

Better analysis for better decisions:facing up to the challenges., Drummond MF;Sculpher MJ;, 2006, Pharmacoeconomics, 24

Is hydrotherapy cost-effective?, Epps H;Ginnelly L;Utley M;Southwood T;Gallivan S;Sculpher M;Woo P;, 2005, Health Technol Assess, 9

Efficiency, equity, and budgetary policies: informing decisions using mathematical programming, Epstein DM;Chalabi Z;Claxton K;Sculpher M;, 2007, Med Decis Making, 27

Representing uncertainty: the role of cost-effectiveness acceptability curves, Fenwick E;Claxton K;Sculpher M;, 2001, Health Econ, 10

The value of implementation and the value of information: combined and uneven development, Fenwick E;Claxton K;Sculpher M;, 2008, Med Decis Making, 28

An iterative Bayesian approach to health technology assessment: application to a policy of preoperative optimization for patients undergoing major elective surgery, Fenwick E;Palmer S;Claxton K;Sculpher M;Abrams K;Sutton A;, 2006, Med Decis Making, 26

Cost-effectiveness of health care interventions: a guide to quantifying stochastic uncertainty and presenting the results of cost-effectiveness analyses., Glick HA;Briggs AH;Polsky D;, 2001, Expert Reviews in Pharmacoeconomics and Outcomes Research, '01:1

Probabilistic analysis and computationally expensive models: Necessary and required?, Griffin S;Claxton K;Hawkins N;Sculpher M;, 2006, Value Health, 9

The impact of reference pricing of nonsteroidal anti-inflammatory agents on the use and costs of analgesic drugs, Grootendorst PV;Marshall JK;Holbrook AM;Dolovich LR;O'Brien BJ;Levy AR;, 2005, Health Serv Res, 40

A simple approach to fitting Bayesian survival models, Gustafson P;Aeschliman D;Levy AR;, 2003, Lifetime Data Anal, 9

Extending logistic regression to model diffuse interactions, Gustafson P;Kazi AM;Levy AR;, 2005, Stat Med, 24

How far do you go? Efficient searching for indirect evidence, Hawkins N;Scott DA;Woods B;, 2009, Med Decis Making, 29

Cost-effectiveness analysis of treatments for chronic disease: Using R to incorporate time dependence of treatment response., Hawkins N;Sculpher M;Epstein D;, 2005, Med Decis Making, 25

Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis, Hoch JS;Briggs AH;Willan AR;, 2002, Health Econ, 11

Internet interventions for long-term conditions: patient and caregiver quality criteria, Kerr C;Murray E;Stevenson F;Gore C;Nazareth I;, 2006, J Med Internet Res, 8

Randomisation in trials: do potential trial participants understand it and find it acceptable?, Kerr C;Robinson E;Stevens A;Braunholtz D;Edwards S;Lilford R;, 2004, J Med Ethics, 30

The impact of describing clinical trial treatments as new or standard, Kerr CE;Robinson EJ;Lilford RJ;Edwards SJ;Braunholtz DA;Stevens AJ;, 2004, Patient Educ Couns, 53

Integrating the patient's perspective into device evaluation trials, Leidy NK;Beusterien K;Sullivan E;Richner R;Muni NI;, 2006, Value Health, 9

Adverse drug events associated with the antidotes for methanol and ethylene glycol poisoning: a comparison of ethanol and fomepizole, Lepik KJ;Levy AR;Sobolev BG;Pursell RA;DeWitt CR;Erhardt GD;Kennedy JR;Daws DE;Brignall JL;, 2009, Ann Emerg Med, 53

Getting the cat back in the bag: reforming the way provinces manage drug expenditures to make them manageable, Levy AR;Gagnon YM;, 2002, Healthc Pap, 3

The extent of patients' understanding of the risk of treatments, Lloyd AJ, 2001, Qual Health Care, 10 Suppl 1

Threats to the estimation of benefit: are preference elicitation methods accurate?, Lloyd AJ, 2003, Health Econ, 12

Patients' ability to recall risk associated with treatment options, Lloyd AJ; Hayes PD;London NJ;Bell PR;Naylor AR;, 1999, Lancet, 353

Meta-analysis of mixed treatment comparisons at multiple follow-up times, Lu G;Ades AE;Sutton AJ;Cooper NJ;Briggs AH;Caldwell DM;, 2007, Stat Med, 26

Estimating mean QALYs in trial-based cost-effectiveness analysis: the importance of controlling for baseline utility, Manca A;Hawkins N;Sculpher MJ;, 2005, Health Econ, 14

Cost-effectiveness analysis using data from multi-national trials: the use of bivariate hierarchical modelling., Manca A;Lambert PC;Sculpher MJ;Rice N;, 2007, Decision Making, 27

Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models, Manca A;Rice N;Sculpher MJ;Briggs AH;, 2005, Health Econ, 14

Impact of reference-based pricing for histamine-2 receptor antagonists and restricted access for proton pump inhibitors in British Columbia, Marshall JK;Grootendorst PV;O'Brien BJ;Dolovich LR;Holbrook AM;Levy AR;, 2002, CMAJ, 166

Bayesian Sensitivity Analysis for Unmeasured Confounding in Observational Studies., McCandless L.C.;Gustafson P;Levy AR;, 2007, Stat Med, 26

Development of Canadian safety indicators for medication use., Nigam R;Mackinnon NJ;Hartnell NR;Levy AR;Gurnham ME;Nguyen TT;, 2008, Healthcare Quarterly, 11

Managing a household survey: a practical example from the KENQOL survey. Kenya Quality of Life, Nyandieka LN;Bowden A;Wanjau J;Fox-Rushby JA;, 2002, Health Policy Plan, 17

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods, O'Brien BJ;Briggs AH;, 2002, Stat Methods Med Res, 11

Building uncertainty into cost-effectiveness rankings: portfolio risk-return tradeoffs and implications for decision rules, O'Brien BJ;Sculpher MJ;, 2000, Med Care, 38

Incorporation of uncertainty in health economic modelling studies, O'Hagan A;McCabe C;Akehurst R;Brennan A;Briggs A;Claxton K;Fenwick E;Fryback D;Sculpher M;Spiegelhalter D;Willan A;, 2005, Pharmacoeconomics, 23

Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment, Philips Z;Bojke L;Sculpher M;Claxton K;Golder S;, 2006, Pharmacoeconomics, 24

Best Practices for cost-effectiveness analysis alongside clinical trials: an ISPOR RCT-CEA task force report, Ramsey S;Willke R;Briggs A;Brown R;Buxton M;Chawla A;Cook J;Glick H;Liljas B;Petrie JR;Reed SD;, 2005, Value Health, 8

Conducting economic evaluations alongside multinational clinical trials: toward a research consensus, Reed SD;Anstrom KJ;Bakhai A;Briggs AH;Califf RM;Cohen DJ;Drummond

MF;Glick HA;Gnanasakthy A;Hlatky MA;O'Brien BJ;Torti FM;Tsiatis AA;Willan AR;Mark DB;Schulman KA;, 2005, Am Heart J, 149

A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results, Reed SD;Dillingham PW;Briggs AH;Veenstra DL;Sullivan SD;, 2003, Med Decis Making, 23

Lay conceptions of the ethical and scientific justifications for random allocation in clinical trials, Robinson EJ;Kerr C;Stevens A;Lilford R;Braunholtz D;Edwards S;, 2004, Soc Sci Med, 58

Lay public's understanding of equipoise and randomisation in randomised controlled trials, Robinson EJ;Kerr CE;Stevens AJ;Lilford RJ;Braunholtz DA;Edwards SJ;Beck SR;Rowley MG;, 2005, Health Technol Assess, 9

Results of the economic evaluation of the first study. A multinational prospective economic evaluation. FIRST Investigators. Flolan International Randomized Survival Trial, Schulman KA;Buxton M;Glick H;Sculpher M;Guzman G;Kong J;Backhouse M;Mauskopf J;Bell L;Eisenberg JM;, 1996, Int J Technol Assess Health Care, 12

The economic evaluation of the FIRST study: design of a prospective analysis alongside a multinational phase III clinical trial. Flolan International Randomized Survival Trial, Schulman KA;Glick H;Buxton M;Sculpher M;Backhouse M;Bell L;Eisenberg JM;, 1996, Control Clin Trials, 17

Evaluating the cost-effectiveness of interventions designed to increase the utilization of evidence-based guidelines, Sculpher M;, 2000, Fam Pract, 17 Suppl 1

Subgroups and heterogeneity in cost-effectiveness analysis, Sculpher M;, 2008, Pharmacoeconomics, 26

The use of quality-adjusted life-years in cost-effectiveness studies, Sculpher M;, 2006, Allergy, 61

Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?, Sculpher M;Claxton K;, 2005, Value Health, 8

Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis, Sculpher M;Gafni A;, 2001, Health Econ, 10

How to assess an article on economic evaluation, Sculpher M;Mercey D;, 1998, Sex Transm Infect, 74

Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study, Sculpher M;Millson D;Meddis D;Poole L;, 2002, Pharmacoeconomics, 20

Analysis sans frontieres: can we ever make economic evaluations generalisable across jurisdictions?, Sculpher MJ;Drummond MF;, 2006, Pharmacoeconomics, 24

Assessing quality in decision analytic cost-effectiveness models: a suggested framework and example of application ., Sculpher MJ;Fenwick E;Claxton K;, 2000, Pharmacoeconomics, 17

Recognizing preference diversity:the use of preference sub-groups in cost effectiveness analysis., Sculpher MJ;Gafni A;, 2001, Health Econ, 10

Income effects of reduced health and health effects of reduced income: implications for health-state valuation, Sculpher MJ;O'Brien BJ;, 2000, Med Decis Making, 20

Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane, Sendi PP;Briggs AH;, 2001, Health Econ, 10

Using the Statecharts paradigm for simulation of patient flow in surgical care., Sobolev B;Harel D;Vasilakis C;Levy AR;, 2008, Health Care Management Sciences, 3

Pharmacoeconomics in COPD: lessons for the future, Starkie HJ;Briggs AH;Chambers MG;, 2008, Int J Chron Obstruct Pulmon Dis, 3

Multinational Trials-Recommendations on the Translations Required, Approaches to Using the Same Language in Different Countries, and the Approaches to Support Pooling the Data: The ISPOR Patient-Reported Outcomes Translation and Linguistic Validation Good Research Practices Task Force Report, Wild D;Eremenco S;Mear I;Martin M;Houchin C;Gawlicki M;Hareendran A;Wiklund I;Chong LY;von MR;Cohen L;Molsen E;, 2008, Value Health,

Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation, Wild D;Grove A;Martin M;Eremenco S;McElroy S;Verjee-Lorenz A;Erikson P;, 2005, Value Health, 8

Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data, Willan AR;Briggs AH;Hoch JS;, 2004, Health Econ, 13

Entanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation., Woolacoot N;Bravo VY;Hawkins N;Kainth A;Khadjesari Z;Misso K;Light K;Asseburg C;Palmer S;Bruce I;Sculpher M;Riemsma R;, 2006, Health Technol Assess, 10